More recently, on October 22, 2024, Novo Nordisk, the creator of the Ozempic (semaglutide) and Wegovy (semaglutide) injections, nominated its semaglutide glucagon-like peptide 1 (GLP-1) medications to be listed
The medication becomes part of your routine, your body adapts, and the therapeutic benefits continue without the disruptive symptoms of early treatment
Most clinical trial participants experienced stable or improved mood, but a small percentage reported increased anxiety, particularly during dose escalation phases
Pipeline Innovation and Differentiation: The development pipeline features next-generation mechanisms beyond single GLP-1 agonism
Never use a vial if the expiration date has already passed, even if the medication looks clear and normalpotency loss is invisible to the eye